US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Defiance Autism Impact ETF

27.18

-0.1786-0.65%

Volume:20

Turnover:551

Market Cap:1.36M

PE:- -

High:27.18

Open:27.36

Low:27.18

Close:27.36

52wk High:29.12

52wk Low:24.54

Shares:50.00K

Float Shares:50.00K

Volume Ratio:0.13

T/O Rate:0.04%

Dividend:0.01

Dividend Rate:0.02%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart

Neurotech raises $4.5m to fund pivotal ASD Phase III trial

Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/ASD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ASD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","market":"US","secType":"STK","nameCN":"Defiance Autism Impact ETF","latestPrice":27.1819,"timestamp":1789502400000,"preClose":27.3605,"halted":0,"volume":20,"delay":0,"changeRate":-0.006527658485773266,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.1786,"latestTime":"09-16 04:10:09 EDT","open":27.3605,"high":27.1819,"low":27.1819,"amount":551,"amplitude":0,"askPrice":43.21,"askSize":100,"bidPrice":10.93,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":27.1819,"nav":27.29,"aum":1364500,"dividendRate":0.00022,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.3605,"preClose":27.1819,"latestTime":"16:10 EDT","volume":6,"amount":163.0914,"timestamp":1789503006921,"change":0.1786,"changeRate":0.006571,"amplitude":0},"volumeRatio":0.13192610396753246},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.13192610396753246,"shares":50000,"dividePrice":0.00597,"high":27.1819,"amplitude":0,"preClose":27.3605,"low":27.1819,"week52Low":24.54,"pbRate":"--","week52High":29.12,"institutionHeld":0,"latestPrice":27.1819,"eps":0,"divideRate":0.00022,"volume":20,"delay":0,"ttmEps":0,"open":27.3605,"prevYearClose":29.12,"prevWeekClose":27.0409,"prevMonthClose":27.6173,"prevQuarterClose":26.76,"fiveDayClose":27.335,"twentyDayClose":27.775,"sixtyDayClose":24.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASD\",params:#limit:5,,,undefined,":[{"date":"2026-06-24","symbol":"ASD","amount":0.00597,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-24","defaultRemindTime":1782307800000,"name":"Defiance Autism Impact ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-24","currency":"USD","dateTimestamp":1782273600000,"payDate":"2026-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASD\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-24","recordDate":"2026-06-24","paymentDate":"2026-06-25","value":0.00597,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659162663","title":"Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162663?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"trial of ML-007C-MA in adults with schizophrenia experiencing an acute. exacerbation of psychosis. The trial met its primary endpoint, with the. 210/3 mg twice-daily dose demonstrating a statistically significant and. clinically meaningful reduction in PANSS total score compared with. -- ML-007C-MA also demonstrated improvement on a prespecified. impairment and significant separation on key secondary endpoints,including CGI-S and the PANSS Marder positive factor.-- ML-007C-MA was generally well tolerated, with no serious or drug-related. severe adverse events and low rates of GI-related discontinuations. Its. clinical profile, including simple initiation, 99% of patients reaching","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2764262908.HKD","LU0868494617.USD","LU0174119429.USD","BK4613","STBQ","LATR","LU0353189763.USD","ASD","LU1316542783.SGD","LU1145028129.USD","LU0006306889.USD","LU2417539215.USD","ADP","FDFF","LU1236620750.USD","LU2361044865.SGD","IE000F7OJYX1.SGD","UYG","IE00B1XK9C88.USD","IE00BJJMRX11.SGD","LU0061474705.USD","LU2404859667.USD","LU1718418525.SGD","LU1084165304.USD","IE0005OL40V9.USD","LU2023250504.SGD","IE00BQXX3C00.GBP","LU2347655073.USD","LU0942090050.USD","IE00B775H168.HKD","LU1623119135.USD","LU0672654240.SGD","VFH","MA","MPLT","LU0965509010.AUD","LU2462157665.USD","LU0056508442.USD","IE000WAW04H5.SGD","LU2168564222.USD","LU1989764748.USD","XLF","LU0234570918.USD","FNCL","BK4559","LU2360107671.USD","IYG","IE00BYQQ9H92.USD","BK4585","IPAY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136535851","title":"Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart","url":"https://stock-news.laohu8.com/highlight/detail?id=1136535851","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136535851?lang=en_us&edition=fundamental","pubTime":"2026-08-08 16:20","pubTimestamp":1786177220,"startTime":"0","endTime":"0","summary":"Qianli Intelligent Driving has announced that its ASD 4.0 assisted driving system has been production-ready and launched in the new smart #1, following its earlier integration in the smart #6. This...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656886125","title":"Neurotech raises $4.5m to fund pivotal ASD Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656886125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656886125?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:38","pubTimestamp":1785800292,"startTime":"0","endTime":"0","summary":"An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has secured binding commitments for a $4.5 mil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","ASD","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654704201","title":"Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654704201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654704201?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:23","pubTimestamp":1785176580,"startTime":"0","endTime":"0","summary":"-- Positive clinical data presented at EHA for iadademstat in first line. in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS. mutations; the triplet continued to demonstrate a favorable safety. gilteritinib continued to show a favorable safety profile and a high CRc. -- Enrollment initiated in Phase II trial of iadademstat in essential. -- U.S. patent granted for vafidemstat in borderline personality disorder. -- Cash position as of June 30, 2026 was $16.7 million ,excluding the gross proceeds of EUR12.0 million  raised in. -- On July 1, 2026, the company entered into a financing agreement with. COFIDES with a commitment to invest EUR25 million in future capital","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCD","BK4144","AMLP","BK4585","BK4588","BK4581","AMZA","BK4161","BK4561","MLPA","UMI","TNGY","BK4590","TPZ","BK4202","EMLP","MDST","ENFR","EIPI","USAI","ASD","EIPX","NCI","ORR","ET","CR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ASD\",params:#limit:6,delay:false,,,undefined,":[]}}